We’ve recently updated our valuation analysis.

RenovoRx Valuation

Is RNXT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RNXT?

Other financial metrics that can be useful for relative valuation.

RNXT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-1.5x
PEG Ration/a

Price to Book Ratio vs Peers

How does RNXT's PB Ratio compare to its peers?

The above table shows the PB ratio for RNXT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.9x
VCNX Vaccinex
4.6xn/aUS$28.9m
SHPH Shuttle Pharmaceuticals Holdings
3.9xn/aUS$32.9m
IMMX Immix Biopharma
2.1x38.2%US$34.3m
ATNX Athenex
1.1x36.8%US$28.0m
RNXT RenovoRx
2.8x20.2%US$22.8m

Price-To-Book vs Peers: RNXT is good value based on its Price-To-Book Ratio (2.8x) compared to the peer average (2.9x).


Price to Earnings Ratio vs Industry

How does RNXT's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Book vs Industry: RNXT is expensive based on its Price-To-Book Ratio (2.8x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is RNXT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RNXT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RNXT's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of RNXT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RNXT ($2.51) is trading below our estimate of fair value ($776.81)

Significantly Below Fair Value: RNXT is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RNXT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.51
US$10.00
+298.4%
10.0%US$11.00US$9.00n/a2
Jan ’24US$2.35
US$10.00
+325.5%
10.0%US$11.00US$9.00n/a2
Dec ’23US$1.88
US$10.00
+431.9%
10.0%US$11.00US$9.00n/a2
Nov ’23US$1.76
US$11.50
+553.4%
21.7%US$14.00US$9.00n/a2
Oct ’23US$2.02
US$11.50
+469.3%
21.7%US$14.00US$9.00n/a2
Sep ’23US$2.18
US$11.50
+427.5%
21.7%US$14.00US$9.00n/a2
Aug ’23US$1.95
US$11.50
+491.3%
21.7%US$14.00US$9.00n/a2
Jul ’23US$2.00
US$11.50
+475.0%
21.7%US$14.00US$9.00n/a2
Jun ’23US$1.93
US$11.50
+495.9%
21.7%US$14.00US$9.00n/a2
May ’23US$1.67
US$11.50
+588.6%
21.7%US$14.00US$9.00n/a2
Apr ’23US$2.87
US$12.50
+335.5%
28.0%US$16.00US$9.00n/a2
Mar ’23US$3.32
US$12.50
+276.5%
28.0%US$16.00US$9.00n/a2
Feb ’23US$3.38
US$15.50
+358.6%
3.2%US$16.00US$15.00n/a2
Jan ’23US$4.84
US$15.50
+220.2%
3.2%US$16.00US$15.00US$2.352
Dec ’22US$7.04
US$15.50
+120.2%
3.2%US$16.00US$15.00US$1.882
Nov ’22US$5.46
US$15.50
+183.9%
3.2%US$16.00US$15.00US$1.762

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies